Business Wire

NIKON-EUROPE

5.10.2021 06:02:13 CEST | Business Wire | Press release

Share
Nikon’s First European Nikon BioImaging Lab Now Open in Leiden

Nikon Europe B.V. has announced that its first European Nikon BioImaging Lab (NBIL) based in the prestigious Leiden Bio Science Park (LBSP) is now officially open.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005909/en/

The official opening took place on September 22nd with a welcome by Ziryan Othman, Team Leader Biotechnology Solutions, Nikon Europe Healthcare Division, followed by addresses by representatives of the organisations involved in helping Nikon Europe B.V. locate and develop the partnership with the Leiden Bio Science Park: Paul Dirkse, Vice Mayor of the City of Leiden; Hilde van der Meer, Commissioner, Netherlands Foreign Investment Agency; Chris van Voorden, Director Foreign Investments of InnovationQuarter; Ida Haisma, Director of Stichting Leiden Bio Science Park; Thijs de Kleer, Director of Biopartner Leiden, and Amito Haarhuis, Director of Rijksmuseum Boerhaave. Bo Kajiwara, Corporate Vice President, Nikon Corporation, Director & President, Nikon Europe B.V. led the opening program for Nikon Europe B.V.

The inauguration and ribbon cutting took place with a symbolic transfer of the famous 17th century van Leeuwenhoek’s microscope, by Amito Haarhuis. World famous for his pioneering work and discoveries in microscopy, Antonie van Leeuwenhoek developed this single-lens microscope, which proved capable of more powerful magnification than other lenses.

Takaharu Sasaoka, Director and Executive Vice President, Healthcare Business Head, Nikon Europe B.V., appreciates the symbolism of the microscope transfer, “It is very appropriate that Nikon, with over 100 years of expertise in optical technology, should open its first European Nikon BioImaging Lab (NBIL-Leiden) here in the Netherlands, the home of Antonie van Leeuwenhoek, the ‘father of microbiology’, whose systematic and extensive research laid the foundations of medical and scientific research. Our mission also is to advance healthcare and provide a better quality of life.

“We are very excited to be located here in the Leiden Bio Science Park, the largest life sciences cluster in the Netherlands, and I would like to thank all the organisations that helped Nikon Europe B.V. locate and develop this partnership. Following the success of our Nikon BioImaging Labs in the US and Japan, NBIL-Leiden will provide services for microscope-based imaging and analysis to the European biotech, pharma, and larger research communities. We are more than a core facility – our full-service capabilities include not only access to Nikon’s innovative microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.”

Daniel Ciepielewski, General Manager, Healthcare Division, Nikon Europe B.V., explains further, “NBIL-Leiden provides full-service imaging, data analysis, and cell cultures using cutting-edge Nikon microscope systems and software solutions, including the new laser scanning confocal AX R, the incubated high content imaging platform LIPSI, deep learning software NIS.ai, research inverted microscope Ti2-E, and compact live-cell imaging microscope BioStudio-T. Unlike other imaging facilities the lab offers full-service cell culture capabilities – our experienced staff is equipped to handle cell thawing, maintenance, expansion, differentiation, and other essential operations.

“The level of service and involvement of the lab is determined individually for each client based on need. Some need only access to equipment and are capable of data acquisition/analysis on their own, while others may require full-service imaging and analysis support. Additional applications include high content imaging and analysis, 3D imaging, fluorescence imaging, high-resolution imaging, color imaging, label-free imaging, cell screening and high throughput imaging, among others. NBIL-Leiden is now open, providing expert imaging support – on demand.”

Nikon Europe B.V. is grateful to InnovationQuarter, the regional economic development agency for the Province of Zuid-Holland, which assisted us in finding the right location and helped coordinate communication to develop the partnership with the Leiden Bio Science Park.

Nikon Europe B.V. is also grateful to the following contributing companies who have partnered with NBIL-Leiden: Clean Air Baker, PHC, Crest Optics, Photometrics, CoolLed, and Precipoint.

For further information, please contact: NBIL.EU@nikon.com
Or please visit www.microscope.healthcare.nikon.com/en_EU/products/cell-screening/nbil .

About Nikon Europe B.V.
Nikon Europe B.V. is the European microscopy arm of Nikon Healthcare Business Unit, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit www.microscope.healthcare.nikon.com/en_EU .

Link:

ClickThru

Social Media:

https://www.facebook.com/nikoninstrumentsinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye